Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention
Best Practice and Research in Clinical Gastroenterology , Volume 27 - Issue 6 p. 933- 947
Gastric cancer is the second leading cause of cancer-related death worldwide. A meta-analysis of seven randomized controlled trials concluded that Helicobacter pylori eradication reduces gastric cancer incidence by 35%. Current consensus is that H. pylori screening and treatment is cost-effective only in high-risk populations. This paper provides an up-to-date overview of the evidence for cost-effectiveness of H. pylori screening and treatment in different population settings and risk levels for H. pylori infection. Ten unique cost-effectiveness or cost-utility analyses were identified. All found that screening for H. pylori to prevent gastric cancer in the general population costs less than $50,000 per LYG. This finding was robust for differences in H. pylori prevalence, gender and ethnicity. Based on limited evidence, re-treatment (for treatment failure), repeated screening, limiting screening and treatment to those with the CagA phenotype, or universal treatment, does not appear to be cost-effective. However, most included studies failed to consider both the broader benefits as well as the adverse effects of widespread use of antibiotics for H. pylori.
|Cost-benefit analysis, Early detection of cancer, Helicobacter pylori, Stomach neoplasms|
|Best Practice and Research in Clinical Gastroenterology|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Lansdorp-Vogelaar, I, & Sharp, L. (2013). Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Practice and Research in Clinical Gastroenterology, 27(6), 933–947. doi:10.1016/j.bpg.2013.09.005